MARKET

TEVA

TEVA

Teva Pharm Ind
NYSE

Real-time Quotes | Nasdaq Last Sale

8.99
+0.04
+0.45%
Pre Market: 8.82 -0.17 -1.89% 09:20 09/20 EDT
OPEN
8.91
PREV CLOSE
8.95
HIGH
9.01
LOW
8.84
VOLUME
23.66K
TURNOVER
--
52 WEEK HIGH
13.30
52 WEEK LOW
8.24
MARKET CAP
9.91B
P/E (TTM)
-2.5148
1D
5D
1M
3M
1Y
5Y
Methotrexate Drug Market- Key Business Opportunities, Impressive Growth Rate and Development Analysis to 2028
Research Nester published a report titled  which delivers a detailed overview of the Methotrexate  Drug market in terms of market segmentation by type, by route of administration, by application, by end-users, by distribution channel, and region.
AmericaNewsHour · 4h ago
Global Myeloproliferative Disorder (MPD) Treatment Market to Grow Owing to Rising Prevalence of Myeloproliferative Disorders Among Individuals till 2029
Research Nester released a report titled which delivers a detailed overview of the global myeloproliferative disorder treatment market in terms of market segmentation by type, treatment, end-user, and by region.
AmericaNewsHour · 4h ago
Growth Hormone Deficiency Market: Company Profiles, Growth Strategy, Developing Technologies, Opportunities and Forecast by Regions till 2028
Research Nester published a report titled  which delivers a detailed overview of the growth hormone deficiency market in terms of market segmentation by application, by route of administration, by distribution channel,  and by region.
AmericaNewsHour · 6h ago
The Possible Reason why Teva (NYSE:TEVA) is Still Trading Below Intrinsic Value
Teva Pharmaceutical Industries Limited (NYSE:TEVA) seems to be undervalued on a fundamental basis. However, sometimes stocks are trading below intrinsic value because there are factors external to the current money making capacity of the company. We will e...
Simply Wall St. · 3d ago
Neuroblastoma Drugs Market By Delivery, Type, Systems, End-User 2028
Research Nester published a report titled "- Global Demand Analysis and Opportunity Outlook 2020-2028" which delivers detailed overview of the neuroblastoma drugs market in terms of market segmentation by drug type, by mechanism type, by treatment type, by...
AmericaNewsHour · 3d ago
Innocan Pharma gained 350% in value this year Is it still a good time to buy? | BreezyScroll
Prospective investors should know that this is just the beginning, as according to financial analysts, InnoCan's stock surged due to the publication of its recent experimental trials. The exposure bolstered market confidence and now many notable experts ar...
MENAFN · 5d ago
Wilson Disease Drugs Market: Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2029
Research Nester has released a report titled "" which delivers detailed overview of the global Wilson disease drugs market in terms of market segmentation by indication, drug type, end-user and by region.
AmericaNewsHour · 6d ago
Teva must face government's kickback claims over Copaxone - judge
Israeli drugmaker Teva Pharmaceutical Industries Ltd must face a lawsuit by the U.S. government accusing it of using kickbacks paid through charitable foundations to boost sales of its multiple sclerosis drug Copaxone, resulting in false claims being submi...
Reuters · 09/10 19:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TEVA. Analyze the recent business situations of Teva Pharm Ind through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TEVA stock price target is 11.47 with a high estimate of 14.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 699
Institutional Holdings: 597.91M
% Owned: 54.24%
Shares Outstanding: 1.10B
TypeInstitutionsShares
Increased
125
27.32M
New
41
2.99M
Decreased
137
36.37M
Sold Out
46
5.66M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Sol Barer
President/Chief Executive Officer/Director
Kaare Schultz
Chief Financial Officer/Executive Vice President
Eliyahu Kalif
Chief Human Resource Officer/Executive Vice President
Galia Inbar
Executive Vice President
Richard Daniell
Executive Vice President
Sven Dethlefs
Executive Vice President
Eric Drape
Executive Vice President
Hafrun Fridriksdottir
Executive Vice President
Mark Sabag
Executive Vice President
Eli Shani
Executive Vice President
David Stark
Chief Accounting Officer
Andrew Weil
Independent Director
Rosemary Crane
Independent Director
Amir Elstein
Independent Director
Jean-Michel Halfon
Independent Director
Gerald Lieberman
Independent Director
Roberto Mignone
Independent Director
Perry Nisen
Independent Director
Nechemia Peres
Independent Director
Ronit Satchi-Fainaro
Independent Director
Janet Vergis
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.072
11/27/2017
08/04/2017
Dividend USD 0.072
08/25/2017
05/16/2017
Dividend USD 0.289
06/01/2017
03/16/2017
Dividend USD 0.289
02/28/2017
11/17/2016
Dividend USD 0.289
12/01/2016
08/08/2016
Dividend USD 0.289
08/18/2016
05/11/2016
Dividend USD 0.289
05/20/2016
02/16/2016
Dividend USD 0.289
02/25/2016
11/02/2015
Dividend USD 0.289
11/13/2015
07/31/2015
Dividend USD 0.289
08/18/2015
05/05/2015
Dividend USD 0.289
05/15/2015
02/20/2015
Dividend USD 0.294
02/17/2015
11/18/2014
Dividend USD 0.27
11/13/2014
08/25/2014
Dividend USD 0.291
08/19/2014
05/20/2014
Dividend USD 0.298
05/16/2014
03/05/2014
Dividend USD 0.293
02/20/2014
11/21/2013
Dividend USD 0.278
11/18/2013
08/21/2013
Dividend USD 0.274
08/16/2013
  • All
  • Financials
  • Insiders
More
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Webull offers kinds of Teva Pharmaceutical Industries Ltd (ADR) stock information, including NYSE:TEVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TEVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TEVA stock methods without spending real money on the virtual paper trading platform.